Wearable Movement Exploration Device with Machine Learning Algorithm for Screening and Tracking Diabetic Neuropathy—A Cross-Sectional, Diagnostic, Comparative Study

TL;DR

A wearable device with machine learning was tested to detect diabetic neuropathy, showing good accuracy and user preference over traditional methods.

Contribution

The Moveo device introduces a novel, wearable, and user-friendly approach for screening diabetic neuropathy using machine learning.

Findings

The Moveo device achieved 82.1% accuracy in detecting diabetic neuropathy.

A strong correlation (up to 0.722) was found between Moveo and electrodiagnostic examination features.

Most participants preferred the Moveo device due to its less painful nature.

Abstract

Background: Diabetic neuropathy is one of the most common complications of diabetes mellitus. The aim of this study is to evaluate the Moveo device, a novel device that uses a machine learning (ML) algorithm to detect and track diabetic neuropathy. The Moveo device comprises 4 sensors positioned on the back of the hands and feet accompanied by a mobile application that gathers data and ML algorithms that are hosted on a cloud platform. The sensors measure movement signals, which are then transferred to the cloud through the mobile application. The cloud triggers a pipeline for feature extraction and subsequently feeds the ML model with these extracted features. Methods: The pilot study included 23 participants. Eleven patients with diabetes and suspected diabetic neuropathy were included in the experimental group. In the control group, 8 patients had suspected radiculopathy, and 4 participants were healthy. All participants underwent an electrodiagnostic examination (EDx) and a Moveo examination, which consists of sensors placed on the feet and back of the participant’s hands and use of the mobile application. The participant performs six tests that are part of a standard neurological examination, and a ML algorithm calculates the probability of diabetic neuropathy. A user experience questionnaire was used to compare participant experiences with regard to both methods. Results: The total accuracy of the algorithm is 82.1%, with 78% sensitivity and 87% specificity. A high linear correlation up to 0.722 was observed between Moveo and EDx features, which underpins the model’s adequacy. The user experience questionnaire revealed that the majority of patients preferred the less painful method. Conclusions: Moveo represents an accurate, easy-to-use device suitable for home environments, showing promising results and potential for future usage.

Figures